Latest period
$18.65B
YoY change
+9.2%
5Y CAGR
+11.3%
Peak year (2025)
$18.26B
Latest annual
$18.26B
Total Equity history chart for Biogen (BIIB) from 1985 to 2025
Latest: $18.26B
Total Equity growth chart for Biogen (BIIB) from 1985 to 2025
Latest: +9.2%
Total Equity history table for Biogen (BIIB) from 1985 to 2025
| 2025 | $18.26B | +9.2% | +$1.54B | ||
| 2024 | $16.72B | +13.0% | +$1.92B | ||
| 2023 | $14.80B | +10.5% | +$1.40B | ||
| 2022 | $13.40B | +23.0% | +$2.50B | ||
| 2021 | $10.90B | +1.8% | +$195.90M | ||
| 2020 | $10.70B | -19.8% | −$2.64B | ||
| 2019 | $13.34B | +2.3% | +$303.60M | ||
| 2018 | $13.04B | +3.4% | +$426.80M | ||
| 2017 | $12.61B | +3.9% | +$472.70M | ||
| 2016 | $12.14B | +29.5% | +$2.77B | ||
| 2015 | $9.37B | -13.3% | −$1.44B | ||
| 2014 | $10.81B | +25.4% | +$2.19B | ||
| 2013 | $8.62B | +23.8% | +$1.66B | ||
| 2012 | $6.96B | +8.3% | +$534.54M | ||
| 2011 | $6.43B | +19.1% | +$1.03B | ||
| 2010 | $5.40B | -13.3% | −$825.02M | ||
| 2009 | $6.22B | +7.2% | +$415.45M | ||
| 2008 | $5.81B | +4.9% | +$271.79M | ||
| 2007 | $5.53B | -22.6% | −$1.62B | ||
| 2006 | $7.15B | +3.5% | +$243.90M | ||
| 2005 | $6.91B | +1.2% | +$79.47M | ||
| 2004 | $6.83B | -3.2% | −$226.93M | ||
| 2003 | $7.05B | +342.1% | +$5.46B | ||
| 2002 | $1.60B | +18.3% | +$246.59M | ||
| 2001 | $1.35B | +21.9% | +$242.43M | ||
| 2000 | $1.11B | +13.0% | +$126.87M | ||
| 1999 | $979.53M | +36.3% | +$260.92M | ||
| 1998 | $718.61M | +34.0% | +$182.32M | ||
| 1997 | $536.29M | +10.7% | +$51.92M | ||
| 1996 | $484.37M | +26.5% | +$101.39M | ||
| 1995 | $382.98M | +16.1% | +$53.05M | ||
| 1994 | $329.93M | +1.5% | +$4.73M | ||
| 1993 | $325.20M | +14.1% | +$40.20M | ||
| 1992 | $285.00M | +19.2% | +$46.00M | ||
| 1991 | $239.00M | +64.0% | +$93.30M | ||
| 1990 | $145.70M | +4.7% | +$6.50M | ||
| 1989 | $139.20M | +104.7% | +$71.20M | ||
| 1988 | $68.00M | +0.1% | +$100.00K | ||
| 1987 | $67.90M | -24.0% | −$21.40M | ||
| 1986 | $89.30M | +19.2% | +$14.40M | ||
| 1985 | $74.90M | — | — |
- 2025$18.26B+9.2%
- 2024$16.72B+13.0%
- 2023$14.80B+10.5%
- 2022$13.40B+23.0%
- 2021$10.90B+1.8%
- 2020$10.70B-19.8%
- 2019$13.34B+2.3%
- 2018$13.04B+3.4%
- 2017$12.61B+3.9%
- 2016$12.14B+29.5%
- 2015$9.37B-13.3%
- 2014$10.81B+25.4%
- 2013$8.62B+23.8%
- 2012$6.96B+8.3%
- 2011$6.43B+19.1%
- 2010$5.40B-13.3%
- 2009$6.22B+7.2%
- 2008$5.81B+4.9%
- 2007$5.53B-22.6%
- 2006$7.15B+3.5%
- 2005$6.91B+1.2%
- 2004$6.83B-3.2%
- 2003$7.05B+342.1%
- 2002$1.60B+18.3%
- 2001$1.35B+21.9%
- 2000$1.11B+13.0%
- 1999$979.53M+36.3%
- 1998$718.61M+34.0%
- 1997$536.29M+10.7%
- 1996$484.37M+26.5%
- 1995$382.98M+16.1%
- 1994$329.93M+1.5%
- 1993$325.20M+14.1%
- 1992$285.00M+19.2%
- 1991$239.00M+64.0%
- 1990$145.70M+4.7%
- 1989$139.20M+104.7%
- 1988$68.00M+0.1%
- 1987$67.90M-24.0%
- 1986$89.30M+19.2%
- 1985$74.90M—
Total Equity values are taken from Biogen's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's latest reported total equity is $18.65B. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual total equity for Biogen (BIIB) came in at $18.26B – grew 9.2% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Biogen total equity compounded at +11.3% per year, sustaining 5 straight years of year-over-year growth.
The highest annual total equity of $18.26B was reported in 2025. The lowest in the available history was $67.90M in 1987.
Biogen Total Equity by Year
Biogen Total Equity 2025: $18.26B
2025's total equity for Biogen came in at $18.26B, grew 9.2% from 2024. This figure represents the highest annual value in the available history.
Biogen Total Equity 2024: $16.72B
Biogen posted total equity of $16.72B in 2024, grew 13.0% from 2023.
Biogen Total Equity 2023: $14.80B
In 2023, Biogen reported total equity of $14.80B, grew 10.5% from 2022.
Biogen Total Equity 2022: $13.40B
Biogen total equity in 2022 was $13.40B, grew 23.0% from 2021.
Biogen Total Equity 2021: $10.90B
Biogen total equity in 2021 was $10.90B.
See more financial history for Biogen (BIIB).
Sector peers by Total Equity
Healthcare peers of Biogen (BIIB), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Biogen (BIIB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation